A. de Roquancourt

发表

The use of dense alumina-alumina ceramic combination in total hip replacement.

A. Roquancourt, P. Boutin, P. Christel, 1988, Journal of biomedical materials research.

Comparison Between 18F-FDG PET Image–Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

M. Hatt, D. Visvikis, D. Groheux, 2013, The Journal of Nuclear Medicine.

Variability of immunohistochemical reactivity on stored paraffin slides.

A. Roquancourt, A. de Roquancourt, V. Meignin, 1998, Journal of clinical pathology.

Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women.

M. Espié, R. Porcher, A. de Roquancourt, 2016, Breast.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer

M. Hatt, D. Visvikis, M. Majdoub, 2015, The Journal of Nuclear Medicine.

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

M. Espié, A. Roquancourt, A. de Roquancourt, 2011, British Journal of Cancer.

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

M. Hatt, D. Groheux, M. Espié, 2013, British Journal of Cancer.

[Breast lobular carcinoma in situ: diagnosis and evolution].

M. Espié, A. de Roquancourt, S. Giacchetti, 2005, Gynecologie, obstetrique & fertilite.

Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.

A. de Roquancourt, P. Cattan, W. Rostène, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[Mycotic infection in immunosuppressed patients. An anatomopathologic study].

A. de Roquancourt, E. Gluckman, R. Kuffer, 1990, Annales de pathologie.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Raphaël Porcher, Marc Espié, Philippe Bertheau, 2013, Breast.

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

M. Espié, D. Rickman, A. de Roquancourt, 2007, PLoS medicine.

Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors

M. Hatt, D. Visvikis, D. Groheux, 2013, Cancer.

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

Raphaël Porcher, Marc Espié, Philippe Bertheau, 2013, Breast Cancer Research.

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

M. Espié, R. Porcher, A. de Roquancourt, 2014, British Journal of Cancer.

Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy.

A. de Roquancourt, P. Cattan, S. Zohar, 2010, Journal of the American College of Surgeons.

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

D. Groheux, M. Espié, S. Chevret, 2022, Cancers.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

M. Hatt, D. Groheux, P. Merlet, 2014, European journal of cancer.

Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

D. Groheux, M. Espié, E. Hindié, 2012, The Journal of Nuclear Medicine.

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

M. Espié, A. de Roquancourt, J. Misset, 2007, British Journal of Cancer.

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal–epithelial interactions

M. Espié, G. Millot, S. Chevret, 2001, The Journal of pathology.

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer

M. Espié, A. de Roquancourt, S. Giacchetti, 2017, Oncotarget.

Hypoparathyroidism preceding Riedel's thyroiditis.

A. de Roquancourt, B. Fantin, N. Belmatoug, 2003, European journal of internal medicine.

Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma.

S. Chevret, C. Chastang, A. de Roquancourt, 2003, Human pathology.

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

R. Rouzier, F. Penault-Llorca, A. de Roquancourt, 2015, The oncologist.

[Epithelial-myoepithelial carcinoma of the salivary glands. Study of 15 cases and review of the literature].

P. Gaulard, A. de Roquancourt, P. Fornés, 1991, Annales de pathologie.

Breast Intracystic Papillary Carcinoma: An Update

M. Espié, J. Calderaro, A. de Roquancourt, 2009, The breast journal.

Breast Carcinoma, Intratumour Heterogeneity and Histological Grading, Using Geostatistics

Jean Paul Rigaut, J. Rigaut, A. de Roquancourt, 2000, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

Monarthritis revealing non-Hodgkin's T cell lymphoma of the synovium.

É. Oksenhendler, A. de Roquancourt, C. Gisselbrecht, 1988, Arthritis and rheumatism.

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC

M. Espié, A. de Roquancourt, S. Giacchetti, 2020, Cancers.

Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer

D. Groheux, P. Merlet, M. Espié, 2012, Journal of the National Cancer Institute.

18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen

Matthieu Resche-Rigon, Marc Espié, Pascal Merlet, 2016, The Journal of Nuclear Medicine.

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.

M. Hatt, D. Visvikis, M. Majdoub, 2015, Radiology.

[Local and general risks of silicone implants].

A. de Roquancourt, J. Servant, P. Banzet, 1988, Chirurgie; memoires de l'Academie de chirurgie.

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

M. Espié, A. Roquancourt, A. de Roquancourt, 2001, British Journal of Cancer.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

M. Hatt, D. Groheux, P. Merlet, 2014, European journal of cancer.